## YaÅ**ž**r Ã**‡**liÅ**k**an

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9008329/publications.pdf

Version: 2024-02-01

59	1,373	15	361022
papers	citations	h-index	g-index
59	59	59	2366
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension After Kidney Transplantation: Analysis of Linked US Registry and Medicare Billing Claims. Transplantation, 2022, 106, 666-675.	1.0	3
2	Oxidative stress and macrophage infiltration in IgA nephropathy. Journal of Nephrology, 2022, 35, 1101-1111.	2.0	7
3	COVIDâ€19 vaccination timing and kidney transplant waitlist management: An international perspective. Transplant Infectious Disease, 2022, 24, e13763.	1.7	8
4	Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. Pediatric Nephrology, 2022, 37, 1981-1994.	1.7	4
5	Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States. American Journal of Transplantation, 2022, 22, 1705-1713.	4.7	32
6	Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. Current Transplantation Reports, 2022, 9, 127-142.	2.0	8
7	Biallelic variants in <scp><i>TTC21B</i></scp> as a rare cause of earlyâ€onset arterial hypertension and tubuloglomerular kidney disease. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 109-120.	1.6	6
8	A case of immune complex mediated tubulointerstitial disease and nephrotic syndrome: anti LRP-2 Nephropathy with diffuse podocyte effacement. Journal of Nephrology, 2021, 34, 915-919.	2.0	3
9	Clinical significance of glomerular C3 deposition in primary membranous nephropathy. Journal of Nephrology, 2021, 34, 581-587.	2.0	11
10	LIMS1 risk genotype and T cell–mediated rejection in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2120-2129.	0.7	8
11	Operational challenges in the COVIDâ€19 era: Asymptomatic infections and vaccination timing. Clinical Transplantation, 2021, 35, e14437.	1.6	16
12	Lower baseline eGFR levels and IgA nephropathy prediction tool. Nephrology, 2021, 26, 1026-1027.	1.6	1
13	Opioids and Kidney Transplantation. Seminars in Nephrology, 2021, 41, 42-53.	1.6	3
14	Clinician and patient attitudes toward use of organs from hepatitis C viremic donors and their impact on acceptance: A contemporary review. Clinical Transplantation, 2021, 35, e14519.	1.6	3
15	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrology Dialysis Transplantation, 2020, 35, 1002-1009.	0.7	66
16	Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis. Pediatric Nephrology, 2020, 35, 927-936.	1.7	7
17	Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality. Transplantation, 2020, 104, 1703-1711.	1.0	7
18	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. Clinical Transplantation, 2020, 34, e14118.	1.6	4

#	Article	IF	CITATIONS
19	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. Kidney International Reports, 2020, 5, 1894-1905.	0.8	54
20	Type IV Collagen Mutations in Familial IgA Nephropathy. Kidney International Reports, 2020, 5, 1075-1078.	0.8	26
21	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nature Communications, 2020, $11$ , $1600$ .	12.8	120
22	Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360, 2020, 1, 1291-1299.	2.1	25
23	SP181COMPARISON OF VARIOUS FEATURES AND OUTCOMES IN ADULT PATIENTS WITH IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS AND C3 GLOMERULOPATHY. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
24	SP184EFFICACY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY C3 GLOMERULONEPHRITIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
25	SP782EFFECTS OF A STANDARDIZED TREATMENT APPROACH ON KIDNEY TRANSPLANT RECIPIENTS WITH ANTIBODY-MEDIATED REJECTION. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	O
26	Co-Deposition of IgM and C3 May Indicate Unfavorable Renal Outcomes in Adult Patients with Primary Focal Segmental Glomerulosclerosis. Kidney and Blood Pressure Research, 2019, 44, 961-972.	2.0	13
27	SP196EFFICACY OF RITUXIMAB IN ADULT PATIENTS WITH REFRACTORY PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
28	Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. New England Journal of Medicine, 2019, 380, 1918-1928.	27.0	63
29	Fabry Disease Prevalence in Renal Replacement Therapy in Turkey. Nephron, 2019, 142, 26-33.	1.8	14
30	Case report: C3 glomerulopathy advancing atypical hemolytic uremic syndrome. Nefrologia, 2018, 38, 450-452.	0.4	1
31	SP690LONG-TERM OUTCOMES OFKIDNEY TRANSPLANTATIONIN GENETIC DISEASES. Nephrology Dialysis Transplantation, 2018, 33, i578-i579.	0.7	0
32	SP148THE EFFECT OF BIOMARKERS AND OXFORD CLASSIFICATION ON PROGRESSION OF Ig A NEPHROPATHY. Nephrology Dialysis Transplantation, 2018, 33, i394-i394.	0.7	0
33	The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection. Renal Failure, 2017, 39, 19-25.	2.1	1
34	Comparison of Renal Anastomosing Hemangiomas in End-Stage and Non–End-Stage Kidneys: A Meta-Analysis With a Report of 2 Cases. International Journal of Surgical Pathology, 2017, 25, 488-496.	0.8	4
35	Serratia marcescens , Morganella morganii , Klebsiella oxytoca related peritonitis attacks in a patient on automated peritoneal dialysis: A case report. Nefrologia, 2017, 37, 350-351.	0.4	3
36	Re-evaluation of glomerulitis using occlusion criteria based on the Banff 2013 revision: a retrospective study. Transplant International, 2017, 30, 579-588.	1.6	3

#	Article	IF	CITATIONS
37	Recurrent and de novo glomerulonephritis following renal transplantation: higher rates of rejection and lower graft survival. International Urology and Nephrology, 2017, 49, 2265-2272.	1.4	4
38	Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?. American Journal of Nephrology, 2017, 46, 96-107.	3.1	36
39	SP127THE CLINICAL SIGNIFICANCE OF PLA2R ANTIBODIES AND C3 DEPOSITION IN THE PROGRESSION OF MEMBRANOUS NEPHROPATHY. Nephrology Dialysis Transplantation, 2016, 31, i128-i128.	0.7	0
40	MP324CONSANGUINITY ASSOCIATED KIDNEY DISEASES IN ADULT TURKISH POPULATION. Nephrology Dialysis Transplantation, 2016, 31, i446-i447.	0.7	0
41	MP516OUTCOME AND RISK FACTORS FOR MORTALITY IN PERITONEAL DIALYSIS PATIENTS: 20 YEARS EXPERIENCE IN A SINGLE TURKISH CENTER. Nephrology Dialysis Transplantation, 2016, 31, i511-i512.	0.7	0
42	MP695RECURRENT GLOMERULAR DISEASES AND ALLOGRAFT REJECTION. Nephrology Dialysis Transplantation, 2016, 31, i570-i571.	0.7	0
43	The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy. Kidney and Blood Pressure Research, 2016, 41, 148-157.	2.0	38
44	High Soluble CD30 Levels and Associated Anti-HLA Antibodies in Patients with Failed Renal Allografts. International Journal of Artificial Organs, 2016, 39, 547-552.	1.4	1
45	The Effects of i>Helicobacter pylori / i>Eradication on Proteinuria in Patients with Primary Glomerulonephritis. International Journal of Nephrology, 2014, 2014, 1-6.	1.3	10
46	Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature Genetics, 2014, 46, 1187-1196.	21.4	505
47	Novel Biomarkers in Glomerular Disease. Advances in Chronic Kidney Disease, 2014, 21, 205-216.	1.4	29
48	Nephrotic sydrome developing in severe ovarian hyperstimulation syndrome. International Journal of Fertility & Sterility, 2014, 7, 345-8.	0.2	1
49	Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation. Balkan Medical Journal, 2013, 30, 37-45.	0.8	2
50	Osteoprotegerin/RANKL Axis and Progression of Coronary Artery Calcification in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 965-973.	4.5	61
51	Cardiac Biomarkers and Noninvasive Predictors of Atherosclerosis in Chronic Peritoneal Dialysis Patients. Kidney and Blood Pressure Research, 2012, 35, 340-348.	2.0	20
52	Comparison of Markers of Appetite and Inflammation Between Hemodialysis Patients With and Without Failed Renal Transplants., 2012, 22, 258-267.		19
53	Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C. BMC Nephrology, 2012, 13, 56.	1.8	15
54	Evaluation of the Medically Complex Living Kidney Donor. Journal of Transplantation, 2012, 2012, 1-6.	0.5	8

## YaŞar ÇaliÅžkan

#	Article	IF	CITATIONS
55	Serum uric acid level is associated with cardiac hypertrophy in renal transplant recipients. Clinical Transplantation, 2011, 25, 368-374.	1.6	9
56	Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrology Dialysis Transplantation, 2010, 25, 2685-2690.	0.7	36
57	Plasma Ghrelin Levels Are Associated with Coronary Microvascular and Endothelial Dysfunction in Peritoneal Dialysis Patients. Renal Failure, 2009, 31, 807-813.	2.1	15
58	Effect of pre-transplant dialysis modality on kidney transplantation outcome. Peritoneal Dialysis International, 2009, 29 Suppl 2, S117-22.	2.3	8
59	Coronary flow reserve dysfunction in hemodialysis and kidney transplant patients. Clinical Transplantation, 2008, 22, 785-793.	1.6	32